392 related articles for article (PubMed ID: 17950578)
21. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
22. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of DMPK: correlation with CTG repeat expansion and fibre type composition in myotonic dystrophy type 1.
Salvatori S; Fanin M; Trevisan CP; Furlan S; Reddy S; Nagy JI; Angelini C
Neurol Sci; 2005 Oct; 26(4):235-42. PubMed ID: 16193250
[TBL] [Abstract][Full Text] [Related]
24. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence.
Kim DH; Langlois MA; Lee KB; Riggs AD; Puymirat J; Rossi JJ
Nucleic Acids Res; 2005; 33(12):3866-74. PubMed ID: 16027111
[TBL] [Abstract][Full Text] [Related]
25. Mass spectrometry analysis of complexes formed by myotonic dystrophy protein kinase (DMPK).
Forner F; Furlan S; Salvatori S
Biochim Biophys Acta; 2010 Jun; 1804(6):1334-41. PubMed ID: 20188867
[TBL] [Abstract][Full Text] [Related]
26. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
[TBL] [Abstract][Full Text] [Related]
27. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
29. Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis.
Santoro M; Masciullo M; Silvestri G; Novelli G; Botta A
Clin Genet; 2017 Oct; 92(4):355-364. PubMed ID: 27991661
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts.
Takarada T; Nishida A; Takeuchi A; Lee T; Takeshima Y; Matsuo M
Brain Dev; 2015 Aug; 37(7):661-8. PubMed ID: 25476247
[TBL] [Abstract][Full Text] [Related]
31. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
[TBL] [Abstract][Full Text] [Related]
32. In situ hybridization analysis of Dmpk mRNA in adult mouse tissues.
Sarkar PS; Han J; Reddy S
Neuromuscul Disord; 2004 Sep; 14(8-9):497-506. PubMed ID: 15336691
[TBL] [Abstract][Full Text] [Related]
33. Transgenic mouse models for myotonic dystrophy type 1 (DM1).
Wansink DG; Wieringa B
Cytogenet Genome Res; 2003; 100(1-4):230-42. PubMed ID: 14526185
[TBL] [Abstract][Full Text] [Related]
34. Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients.
Grande V; Hathazi D; O'Connor E; Marteau T; Schara-Schmidt U; Hentschel A; Gourdon G; Nikolenko N; Lochmüller H; Roos A
J Neuromuscul Dis; 2021; 8(4):603-619. PubMed ID: 33682722
[TBL] [Abstract][Full Text] [Related]
35. RNA pathogenesis of the myotonic dystrophies.
Day JW; Ranum LP
Neuromuscul Disord; 2005 Jan; 15(1):5-16. PubMed ID: 15639115
[TBL] [Abstract][Full Text] [Related]
36. Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues.
Rinaldi F; Terracciano C; Pisani V; Massa R; Loro E; Vergani L; Di Girolamo S; Angelini C; Gourdon G; Novelli G; Botta A
Neurobiol Dis; 2012 Jan; 45(1):264-71. PubMed ID: 21872659
[TBL] [Abstract][Full Text] [Related]
37. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
[TBL] [Abstract][Full Text] [Related]
38. Respiratory failure in a mouse model of myotonic dystrophy does not correlate with the CTG repeat length.
Panaite PA; Kuntzer T; Gourdon G; Barakat-Walter I
Respir Physiol Neurobiol; 2013 Oct; 189(1):22-6. PubMed ID: 23811192
[TBL] [Abstract][Full Text] [Related]
39. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
40. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
Sobczak K; Wheeler TM; Wang W; Thornton CA
Mol Ther; 2013 Feb; 21(2):380-7. PubMed ID: 23183533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
